JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Groshar, D.
Right arrow Articles by Zuckerman, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Groshar, D.
Right arrow Articles by Zuckerman, E.
Journal of Nuclear Medicine Vol. 43 No. 3 312-317
© 2002 by Society of Nuclear Medicine


Clinical Investigations

Quantitation of Liver and Spleen Uptake of 99mTc-Phytate Colloid Using SPECT: Detection of Liver Cirrhosis

David Groshar, MD1, Gleb Slobodin, MD2 and Eli Zuckerman, MD2

1 Department of Nuclear Medicine, Bnai Zion Medical Center, Technion-Israel Institute of Technology, Haifa, Israel
2 Liver Unit, Bnai Zion Medical Center, Technion-Israel Institute of Technology, Haifa, Israel

The purpose of this study was to assess the diagnostic performance of quantitative SPECT of 99mTc-phytate colloid in detecting liver cirrhosis and to assess the correlation between the SPECT results and the severity of disease. Methods: Quantitative SPECT was performed on 60 patients (38 men, 22 women; mean age, 62.4 y) with liver cirrhosis and 36 control patients (21 men, 15 women; mean age, 58.7 y) without liver cirrhosis, and the results for the 2 groups were compared. Correlation with Child–Pugh classification and receiver operating characteristic methodology was used to analyze the results. Results: Cirrhotic livers had a lower total uptake than did control livers (35.6% ± 13.5% vs. 61.6% ± 10.2%, P < 0.0001). This reduced uptake was associated with a significantly reduced percentage injected dose per cubic centimeter (%ID/cm3) (0.024 ± 0.01 vs. 0.044 ± 0.01, P < 0.0001). The volume, 1,467 ± 348 cm3, was similar to that of control livers (1,487 ± 397 cm3, P = 0.80). Total uptake in the spleen was significantly greater in patients with cirrhosis than in control patients (24.9% ± 12% vs. 7.6% ± 3.2%, P < 0.0001) because of an increased volume (833 ± 460 cm3 vs. 239 ± 90 cm3, P < 0.0001). The %ID/cm3 of spleen tissue was 0.033 ± 0.01, which was similar to the value in control patients (0.032 ± 0.01, P = 0.88). Spleen volume showed the best performance in detecting liver cirrhosis, with a mean area under the curve of 0.97 (95% CI = 0.91–0.99). The severity of liver disease correlated better with total liver uptake (r = -0.68, 95% CI = -0.80 to -0.52, P < 0.0001). Conclusion: Individual SPECT quantitation of 99mTc-phytate colloid uptake in the liver and spleen could be used as a noninvasive method to separate normal from cirrhotic livers and to evaluate the severity of disease.

Key Words: liver cirrhosis • SPECT • radionuclide • 99mTc-phytate • quantitation







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.